Related Experiment Video
Updated: Jul 10, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
Determining the Cancer Center priorities at the Wilmot Cancer Institute: A proposed framework informed by an
Francisco Cartujano-Barrera1,2, Ana Paula Cupertino1,3, Emily Hayes1
1Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States.
Abstract:
Current National Cancer Institute (NCI) Cancer Center Support Grant guidelines include a Community Outreach and Engagement merit descriptor related to the justification of Cancer Center priorities. Unfortunately, there is limited guidance and published literature on the process of determining the Cancer Center priorities. The purpose of this commentary is to propose a framework for Cancer Center prioritization, informed by the academic-community collaborative approach that the Wilmot Cancer Institute (Wilmot) at the University of Rochester implemented as part of a successful application for NCI designation. We first defined Wilmot's catchment area and curated data on the cancer burden in that area. We then collaborated with program leaders to assess Wilmot's capacity to address the cancer burden in its catchment area. We iteratively worked with our Community Cancer Action Council (CCAC) to determine the Cancer Center priorities. Cancer incidence, mortality, risk factors, and screening data, as well as ongoing research from Wilmot's scientific programs, were the factors that Wilmot leaders and CCAC partners considered to make this determination. Thus, (1) tobacco-related cancers (ie, bladder, esophageal, head and neck, larynx, and lung cancers; including addressing tobacco prevention and cessation, and promoting lung cancer screening), (2) hematologic malignancies (ie, leukemia and lymphoma), and (3) pancreatic and hepatobiliary cancers were determined as the Cancer Center priorities. These Cancer Center priorities have informed research and outreach at Wilmot.
Related Concept Videos
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis

